Quality | Association for Accessible Medicines
COVID-19 and AAM - FAQ's and resources from the U.S. generics and biosimilars industry.


AAM Member Fresenius Kabi Testifies Before Congress on Drug Compounding

On January 30, Fresenius Kabi USA Vice President of Regulatory Affairs Molly Ventrelli testified before Congress on compounding.

The House Energy & Commerce Committee held a hearing on “Examining Implementation of the Compounding Quality Act.” Fresenius Kabi is a global health care company specializing in lifesaving medicines and technologies for infusion, transfusion and clinical nutrition.

The company operates 18 compounding centers around the world, and is in the process of launching its first U.S.-based, 503B compounding center in suburban Boston.

What’s the Difference Between Generics and Brand-Name Drugs?

While the pills you receive at the pharmacy counter may look slightly different from the brand, generic medicines work the same as costlier brand-name products. They have the same active ingredients, and the manufacturing and packaging must pass the same quality standards.

The U.S. Food and Drug Administration (FDA) requires generic drugs to have the same performance and quality as brand name drugs. The FDA says: “When a generic drug product is approved, it has met rigorous standards established by the FDA with respect to identity, strength, quality, purity, and potency.”

Subscribe to Quality

Association for Accessible Medicines


Sign-up for Updates

Receive relevant industry news, event information and the latest resources on biosimilars and generic medicines.

Stay Connected

For the latest updates, follow us on social media.